Kala Pharmaceuticals Total Debt vs. Shares Owned By Insiders
KALA Stock | USD 6.99 0.06 0.87% |
For Kala Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kala Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kala Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kala Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kala Pharmaceuticals over time as well as its relative position and ranking within its peers.
Kala |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kala Pharmaceuticals Shares Owned By Insiders vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kala Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kala Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Kala Pharmaceuticals is rated below average in total debt category among its peers. It is rated below average in shares owned by insiders category among its peers . The ratio of Total Debt to Shares Owned By Insiders for Kala Pharmaceuticals is about 8,824,830 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kala Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Kala Total Debt vs. Competition
Kala Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 5.86 Billion. Kala Pharmaceuticals maintains roughly 36.32 Million in total debt contributing less than 1% to equities under Health Care industry.
Kala Shares Owned By Insiders vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Kala Pharmaceuticals |
| = | 36.32 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Kala Pharmaceuticals |
| = | 4.12 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Kala Shares Owned By Insiders Comparison
Kala Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Kala Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kala Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kala Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Kala Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Kala Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts. Kala Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 192 people.
Kala Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kala Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kala Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kala Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Kala Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
All Next | Launch Module |
Use Investing Themes to Complement your Kala Pharmaceuticals position
In addition to having Kala Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Printing and Publishing Thematic Idea Now
Printing and Publishing
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
View All Next | Launch |
Check out Correlation Analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
To fully project Kala Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Kala Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Kala Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.